Cestode Infestations. Hydatid Disease and Cysticercosis

Infectious Disease Clinics of North America

Volumn 26, Issue 2, 2012, Pages 421-435

  Brunetti, Enrico ^a   White, A Clinton ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alveolar echinococcosis; Cestodes; Cystic echinococcosis; Cysticercosis; Neurocysticercosis; Tapeworms

Indexed keywords

ALBENDAZOLE; ANTIPARASITIC AGENT; BENZIMIDAZOLE; CARBAMAZEPINE; CORTICOSTEROID; PHENYTOIN; PLACEBO; PRAZIQUANTEL; PREDNISONE;

ALOPECIA; ASPIRATION BIOPSY; BRAIN CALCIFICATION; BRAIN RADIOGRAPHY; BRAIN SURGERY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYSTICERCOSIS; CYSTICERCUS (CESTODE LARVA); CYTOPENIA; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ECHINOCOCCOSIS; ECHINOCOCCUS MULTILOCULARIS; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; LAPAROSCOPIC SURGERY; LIVER TOXICITY; NEUROCYSTICERCOSIS; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE HYDROCEPHALUS; PARASITE LOCALIZATION; PARASITE TRANSMISSION; REVIEW; SEIZURE; SEROLOGY; SIDE EFFECT; SPARGANOSIS; TAENIA SOLIUM; TREATMENT DURATION; TREATMENT PLANNING;

ANIMALS; ANTHELMINTICS; ANTICONVULSANTS; CYSTICERCOSIS; CYSTICERCUS; DEVELOPING COUNTRIES; ECHINOCOCCOSIS; ECHINOCOCCUS; HUMANS; NEUROCYSTICERCOSIS;

EID: 84861476289     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.02.001     Document Type: Review

References (49)

1. Thompson R.C. The taxonomy, phylogeny and transmission of Echinococcus. Exp Parasitol 2008, 119(4):439-446.
2. Macpherson C.N., Bartholomot B., Frider B. Application of ultrasound in diagnosis, treatment, epidemiology, public health and control of Echinococcus granulosus and E. multilocularis. Parasitology 2003, 127(Suppl):S21-S35.
3. WHO, IWGE International classification of ultrasound images in cystic echinococcosis for application in clinical and field epidemiological settings. Acta Trop 2003, 85(2):253-261.
4. Brunetti E., Junghanss T. Update on cystic hydatid disease. Curr Opin Infect Dis 2009, 22(5):497-502.
5. Hosch W., Junghanss T., Stojkovic M., et al. Metabolic viability assessment of cystic echinococcosis using high-field (1)H MRS of cyst contents. NMR Biomed 2008, 21(7):734-754.
6. Hosch W., Stojkovic M., Janisch T., et al. MR imaging for diagnosing cysto-biliary fistulas in cystic echinococcosis. Eur J Radiol 2008, 66(2):262-267.
7. Brunetti E., Kern P., Vuitton D.A. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010, 114(1):1-16.
8. Menezes da Silva A. Hydatid cyst of the liver-criteria for the selection of appropriate treatment. Acta Trop 2003, 85(2):237-242.
9. Dziri C., Haouet K., Fingerhut A., et al. Management of cystic echinococcosis complications and dissemination: where is the evidence?. World J Surg 2009, 33(6):1266-1273.
10. Bygott J.M., Chiodini P.L. Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease?. Acta Trop 2009, 111(2):95-101.
11. Neumayr A., Troia G., de Bernardis C., et al. Justified concern or exaggerated fear: the risk of anaphylaxis in percutaneous treatment of cystic echinococcosis-a systematic literature review. PLoS Negl Trop Dis 2011, 5(6):e1154.
12. Kabaalioglu A., Ceken K., Alimoglu E., et al. Percutaneous imaging-guided treatment of hydatid liver cysts: do long-term results make it a first choice?. Eur J Radiol 2006, 59(1):65-73.
13. Golemanov B., Grigorov N., Mitova R., et al. Efficacy and safety of PAIR for cystic echinococcosis: experience on a large series of patients from Bulgaria. Am J Trop Med Hyg 2011, 84(1):48-51.
14. Stojkovic M., Zwahlen M., Teggi A., et al. Treatment response of cystic echinococcosis to benzimidazoles: a systematic review. PLoS Negl Trop Dis 2009, 3(9):e524.
15. Brunetti E., Garcia H.H., Junghanss T. Cystic echinococcosis: chronic, complex, and still neglected. PLoS Negl Trop Dis 2011, 5(7):e1146.
16. Torgerson P.R., Keller K., Magnotta M., et al. The global burden of alveolar echinococcosis. PLoS Negl Trop Dis 2010, 4(6):e722.
17. Romig T. Echinococcus multilocularis in Europe-state of the art. Vet Res Commun 2009, 33(Suppl 1):31-34.
18. Eckert J., Deplazes P. Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev 2004, 17(1):107-135.
19. Torgerson P.R., Schweiger A., Deplazes P., et al. Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J Hepatol 2008, 49(1):72-77.
20. Bresson-Hadni S., Blagosklonov O., Knapp J., et al. Should possible recurrence of disease contraindicate liver transplantation in patients with end-stage alveolar echinococcosis? A 20-year follow-up study. Liver Transpl 2011, 17(7):855-865.
21. Ndimubanzi P.C., Carabin H., Budke C.M., et al. A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis 2010, 4(11):e870.
22. Goel D., Dhanai J.S., Agarwal A., et al. Neurocysticercosis and its impact on crude prevalence rate of epilepsy in an Indian community. Neurol India 2011, 59(1):37-40.
23. Raghava M.V., Prabhakaran V., Jayaraman T., et al. Detecting spatial clusters of Taenia solium infections in a rural block in South India. Trans R Soc Trop Med Hyg 2010, 104(9):601-612.
24. Villaran M.V., Montano S.M., Gonzalvez G., et al. Epilepsy and neurocysticercosis: an incidence study in a Peruvian rural population. Neuroepidemiology 2009, 33(1):25-31.
25. Montano S.M., Villaran M.V., Ylquimiche L., et al. Neurocysticercosis: association between seizures, serology, and brain CT in rural Peru. Neurology 2005, 65(2):229-233.
26. Medina M.T., Duron R.M., Martinez L., et al. Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salamástudy. Epilepsia 2005, 46(1):124-131.
27. Blocher J., Schmutzhard E., Wilkins P.P., et al. A cross-sectional study of people with epilepsy and neurocysticercosis in Tanzania: clinical characteristics and diagnostic approaches. PLoS Negl Trop Dis 2011, 5(6):e1185.
28. Foyaca-Sibat H., Cowan L.D., Carabin H., et al. Accuracy of serological testing for the diagnosis of prevalent neurocysticercosis in outpatients with epilepsy, Eastern Cape Province, South Africa. PLoS Negl Trop Dis 2009, 3(12):e562.
29. Praet N., Speybroeck N., Manzanedo R., et al. The disease burden of Taenia solium cysticercosis in Cameroon. PLoS Negl Trop Dis 2009, 3(3):e406.
30. del la Garza Y., Graviss E.A., Daver N.G., et al. Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg 2005, 73(4):766-770.
31. Serpa J.A., Graviss E.A., Kass J.S., et al. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) 2011, 90(1):81-86.
32. Nash T.E., Pretell E.J., Lescano A.G., et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol 2008, 7(12):1099-1105.
33. Nash T.E., Del Brutto O.H., Butman J.A., et al. Calcific neurocysticercosis and epileptogenesis. Neurology 2004, 62(11):1934-1938.
34. Nash T.E., Garcia H.H. Diagnosis and treatment of neurocysticercosis. Nat Rev Neurol 2011, 7(10):584-594.
35. Tsang V.C., Brand J.A., Boyer A.E. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis 1989, 159(1):50-59.
36. Wilson M., Bryan R.T., Fried J.A., et al. Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis 1991, 164(5):1007-1009.
37. Rodriguez S., Dorny P., Tsang V.C., et al. Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. J Infect Dis 2009, 199(9):1345-1352.
38. White A.C. New developments in the management of neurocysticercosis. J Infect Dis 2009, 199(9):1261-1262.
39. Nash T.E., Singh G., White A.C., et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 2006, 67(7):1120-1127.
40. Rangel-Castilla L., Serpa J.A., Gopinath S.P., et al. Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg 2009, 80(3):373-378.
41. Proano J.V., Madrazo I., Avelar F., et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001, 345(12):879-885.
42. Garcia H.H., Pretell E.J., Gilman R.H., et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004, 350(3):249-258.
43. Del Brutto O.H., Roos K.L., Coffey C.S., et al. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 2006, 145(1):43-51.
44. Carpio A., Kelvin E.A., Bagiella E., et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008, 79(9):1050-1055.
45. Abba K., Ramaratnam S., Ranganathan L.N. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev 2010, 1. CD000215.
46. Garcia H.H., Lescano A.G., Lanchote V.L., et al. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. Br J Clin Pharmacol 2011, 72(1):77-84.
47. Kaur S., Singhi P., Singhi S., et al. Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J 2009, 28(5):403-406.
48. Li M.W., Song H.Q., Li C., et al. Sparganosis in mainland China. Int J Infect Dis 2011, 15(3):e154-e156.
49. Ing M.B., Schantz P.M., Turner J.A. Human coenurosis in North America: case reports and review. Clin Infect Dis 1998, 27(3):519-523.